PMID- 22490797
OWN - NLM
STAT- MEDLINE
DCOM- 20121231
LR  - 20120411
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 92
IP  - 4
DP  - 2012 Jan 31
TI  - [Prevalence status and mutation pattern of H221Y in subtype B' of HIV-1].
PG  - 250-3
AB  - OBJECTIVE: To explore the prevalence and mutation pattern of H221Y at reverse 
      transcriptase (RT) among the subtype B' of human immunodeficiency virus1 (HIV-1) 
      in antiviral therapy-failure patients. METHODS: A total of 1363 sequences, 
      comprising of 1205 therapy-failure individuals and 158 therapy-naive individuals, 
      were submitted to the Stanford HIV drug resistance database (SHDB) to analyze the 
      frequency and mutation pattern of H221Y. RESULTS: The prevalence of mutation 
      H221Y in the therapy-failure population was significantly higher than that of the 
      therapy-naive (6.59% vs 0.60%) (chi(2) = 6.59, P = 0.027). The emergence of H221Y 
      usually accompanied the position mutations of T215, M184, K103 and Y181 of RT, 
      and the pattern of TAMs/H221Y/Y181C/I was common. Frequency of H221Y in the 
      regimen of AZT/ddI/NVP was more popular than the other 4 regimens (14.6% vs 3.5%, 
      4.9%, 2.3%, 2.6%, all P < 0.01). CONCLUSION: With a unique mutation pattern, 
      H221Y has a low prevalence in the individuals of first-line therapy-failure 
      patients.
FAU - Li, Han-ping
AU  - Li HP
AD  - State Key Laboratory of Pathogen & Biosecurity, Institute of Microbiology & 
      Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
FAU - Guo, Wei
AU  - Guo W
FAU - Liu, Yong-jian
AU  - Liu YJ
FAU - Bao, Zuo-yi
AU  - Bao ZY
FAU - Li, Lin
AU  - Li L
FAU - Zhuang, Dao-min
AU  - Zhuang DM
FAU - Liu, Si-yang
AU  - Liu SY
FAU - Wang, Xiao-lin
AU  - Wang XL
FAU - Li, Jing-yun
AU  - Li JY
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/virology
MH  - Adult
MH  - Aged
MH  - Antiretroviral Therapy, Highly Active
MH  - Drug Resistance, Viral/*genetics
MH  - Female
MH  - Genes, Viral/genetics
MH  - Genotype
MH  - HIV-1/*genetics/isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Young Adult
EDAT- 2012/04/12 06:00
MHDA- 2013/01/01 06:00
CRDT- 2012/04/12 06:00
PHST- 2012/04/12 06:00 [entrez]
PHST- 2012/04/12 06:00 [pubmed]
PHST- 2013/01/01 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2012 Jan 31;92(4):250-3.